Cargando…

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Wen, Lei, Pengfei, Liu, Xin, Li, Qin, Cheng, Xiangyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600068/
https://www.ncbi.nlm.nih.gov/pubmed/34804000
http://dx.doi.org/10.3389/fimmu.2021.686057
_version_ 1784601069411631104
author Dong, Wen
Lei, Pengfei
Liu, Xin
Li, Qin
Cheng, Xiangyang
author_facet Dong, Wen
Lei, Pengfei
Liu, Xin
Li, Qin
Cheng, Xiangyang
author_sort Dong, Wen
collection PubMed
description Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutations in ALK gene, other mechanisms might contribute to tumor resistance to ALK tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a case of PD-L1-overexpressing lung adenocarcinoma that harbors both EML4-ALK gene rearrangement and BRAF mutation. In particular, a second molecular analysis after resistance to first- and second-generation ALK-TKIs revealed a high PD-L1 expression and tumor mutation burden. Therefore, treatment with nivolumab monotherapy, an anti-PD-1 inhibitor, was started and the patient achieved complete remission. This case report suggested that PD-1 inhibitors might be an effective treatment option for patients with multiple gene-driven PD-L1-expressing NSCLC harboring ALK gene rearrangement.
format Online
Article
Text
id pubmed-8600068
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86000682021-11-19 Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Dong, Wen Lei, Pengfei Liu, Xin Li, Qin Cheng, Xiangyang Front Immunol Immunology Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutations in ALK gene, other mechanisms might contribute to tumor resistance to ALK tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a case of PD-L1-overexpressing lung adenocarcinoma that harbors both EML4-ALK gene rearrangement and BRAF mutation. In particular, a second molecular analysis after resistance to first- and second-generation ALK-TKIs revealed a high PD-L1 expression and tumor mutation burden. Therefore, treatment with nivolumab monotherapy, an anti-PD-1 inhibitor, was started and the patient achieved complete remission. This case report suggested that PD-1 inhibitors might be an effective treatment option for patients with multiple gene-driven PD-L1-expressing NSCLC harboring ALK gene rearrangement. Frontiers Media S.A. 2021-11-04 /pmc/articles/PMC8600068/ /pubmed/34804000 http://dx.doi.org/10.3389/fimmu.2021.686057 Text en Copyright © 2021 Dong, Lei, Liu, Li and Cheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Dong, Wen
Lei, Pengfei
Liu, Xin
Li, Qin
Cheng, Xiangyang
Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_full Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_fullStr Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_full_unstemmed Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_short Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_sort case report: complete response to nivolumab in a patient with programmed cell death 1 ligand 1-positive and multiple gene-driven anaplastic lymphoma kinase tyrosine kinase inhibitor-resistant lung adenocarcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600068/
https://www.ncbi.nlm.nih.gov/pubmed/34804000
http://dx.doi.org/10.3389/fimmu.2021.686057
work_keys_str_mv AT dongwen casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma
AT leipengfei casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma
AT liuxin casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma
AT liqin casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma
AT chengxiangyang casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma